NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-DE-21-015 from the NIH Guide for Grants and Contracts
Notice NOT-HS-22-009 from the NIH Guide for Grants and Contracts
Notice NOT-MH-22-055 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-073 from the NIH Guide for Grants and Contracts. Through this I-Corps at NIH program Funding Opportunity Announcement (FOA), NIH and CDC provide administrative supplement awards to active SBIR (NIH and CDC) and STTR Phase I (NIH only) grantees/awardees. The I-Corps at NIH mission is to empower entrepreneurs in developing and validating a strategic business model through diverse customer discovery in order to meet unmet clinical needs. I-Corps enables and accelerates the transformation of invention to impact SBIR and STTR Phase I awardees in a no-cost extension are eligible as long as, if selected, their no cost extension covers the entire duration of I-Corps at NIH cohort. The program provides three-member project teams with access to instruction and mentoring to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact Scientific/Research staff for more information about the program before applying.
Funding Opportunity PAR-22-067 from the NIH Guide for Grants and Contracts. Reissue of PAR-19-028 This Funding Opportunity Announcement (FOA) solicits research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is to build a foundation for understanding how interactions within and among brain regions change over pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories in rodents or non-human primates and investigate questions using in vivo neural measures in awake, behaving animals. This FOA uses the R21 grant mechanism, whereas its companion funding opportunity seeks shorter, higher-risk R01 grant applications.
Funding Opportunity RFA-NS-22-014 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for the Clinical Coordinating Center (CCC) of Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN). SIREN will enable conduct of high-quality, multi-site clinical trials to improve the outcomes for patients with neurologic, cardiac, respiratory, hematologic and trauma emergency events. SIREN will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and up to 10 clinical centers (Hubs). The CCC will facilitate implementation of clinical trials and will promote high quality and efficient timeliness in trial execution through such methods as master trial agreements and a central Institutional Review Board. SIREN will implement a total of at least four large (1,000 patient) simple, pragmatic clinical trials in the emergency department and pre-hospital settings. The clinical trials will be meritorious, peerreviewed projects which will be awarded under separate funding announcements.
Funding Opportunity RFA-NS-22-013 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for the Data Coordinating Center (DCC) for Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN). SIREN will enable conduct of high-quality, multi-site clinical trials to improve the outcomes for patients with neurologic, cardiac, respiratory, hematologic, and trauma emergency events. SIREN will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and up to 10 clinical centers (Hubs). The DCC will have responsibility for data management, data quality, statistical analysis, Data Safety Monitoring Board(s) (DSMB) and reporting to regulatory and oversight groups. SIREN will implement a total of at least four large (1,000 patient) simple, pragmatic clinical trials in the emergency department and pre-hospital settings. The clinical trials will be meritorious, peerreviewed projects which will be awarded under separate funding announcements.
Funding Opportunity RFA-NS-22-015 from the NIH Guide for Grants and Contracts. (Reissue of RFA-NS-16-016) The purpose of this funding opportunity announcement (FOA) is to invite applications from new and existing sites to serve as Clinical Centers (Hubs) in the SIREN Network. SIREN conduct of several multi-center Phase III clinical trials, to improve the outcomes for patients with neurologic, cardiac, respiratory, hematologic, and traumatic conditions. SIREN is made up of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and 11 clinical centers (Hubs). A Hub is usually an academic center or tertiary referral center which actively enrolls patients into all of the clinical trial performed in SIREN. Hubs also provide scientific leadership and administrative oversight to their multiple satellite sites ("Spokes"). Together the Hub and Spokes provide access to a large and varying patient population for clinical trials. SIREN performs a number of simple, pragmatic clinical trials in the emergency department and pre-hospital settings. The clinical trials are meritorious, peerreviewed projects which are awarded under separate funding announcements.
Funding Opportunity PAR-21-343 from the NIH Guide for Grants and Contracts. The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs). Specifically, the program seeks to broaden and strengthen translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH), and by providing support for extramural investigators to take advantage of the unique research opportunities available at the NIH Clinical Center by conducting clinical research projects in collaboration with NIH intramural investigators.
Funding Opportunity PAR-21-342 from the NIH Guide for Grants and Contracts. The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs). Specifically, the program seeks to broaden and strengthen translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH), and by providing support for extramural investigators to take advantage of the unique research opportunities available at the NIH Clinical Center by conducting clinical research projects in collaboration with NIH intramural investigators.
Notice NOT-MH-22-045 from the NIH Guide for Grants and Contracts
Notice NOT-HL-22-005 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-027 from the NIH Guide for Grants and Contracts
Notice NOT-DA-21-060 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-018 from the NIH Guide for Grants and Contracts
Notice NOT-AI-22-011 from the NIH Guide for Grants and Contracts
Notice NOT-DE-21-020 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-EY-21-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) aims to support collaborative studies of a unique resource of patient-derived induced pluripotent stem cell (iPSC) lines generated by the NEI age-related macular degeneration (AMD) Integrative Biology Initiative. This resource also includes clinical, genomic, and imaging data from the patients from which these cells were derived, and a set of isogenic control cell lines in which the risk allele(s) have been corrected. These cell lines and clinical data are from patients with AMD carrying high prevalence risk alleles selected from the Age-Related Eye Disease Study 2 (AREDS2). The goal of this FOA is to determine if these iPSC-derived cell lines can be used to discover the underlying pathophysiology of AMD. Collaborative effort is highly encouraged with investigators bringing in the needed areas of expertise for successful projects.
Funding Opportunity RFA-RM-22-006 from the NIH Guide for Grants and Contracts. The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) with the vision of alleviating suffering from childhood cancer and structural birth defects by fostering collaborative research to uncover the etiology of these diseases and supporting data sharing within the pediatric research community. Kids First has established and continues to develop a Data Resource including a large collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. This FOA is intended to engage experts in a variety of activities that will enhance the utility of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets and resources. These activities should strengthen future analyses of Kids First datasets by the broader researcher community with the ultimate goal of improving diagnostic capabilities and therapies for children and their families affected by these conditions.
Notice NOT-CE-22-001 from the NIH Guide for Grants and Contracts